Nonsteroidal antiinflammatory drug use and lung cancer: A metaanalysis

Chest

Volumn 127, Issue 3, 2005, Pages 748-754

  Khuder, Sadik A ^a   Herial, Nabeel A ^a   Mutgi, Anand B ^a   Federman, Douglas J ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Aspirin; Lung cancer; Metaanalysis; Nonsteroidal antiinflammatory drug; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SMOKING; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; DOSE RESPONSE; LUNG TUMOR; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; RISK;

EID: 15844400550     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.3.748     Document Type: Article

References (43)

1. Statistics and Information Department. Vital statistics of Japan, Vol. 3. Tokyo, Japan: Ministry of Health and Welfare, 1998; 384-411
2. Cancer statistics. Atlanta, GA: American Cancer Society, 2004
3. The health benefits of smoking cessation: a report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, 1990; publication No. (CDC) 90-8416
4. Rosenberg L, Louik C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82:2326-2333
5. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81:62-68
6. Khuder SA, Mutgi AB. NSAID and breast cancer: a meta-analysis. Br J Cancer 2001; 84:1188-1192
7. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 8:101-129
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1987; 7:77-188
9. Tweedie RL, Mengersen KL. Meta-analytic approaches to dose-response relationship, with application in studies of lung cancer and exposure to environmental tobacco smoke. Stat Med 1995; 14:545-569
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
11. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296:313-316
12. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299:1247-1250
13. Thun MJ, Narnboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53:1322-1327
14. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138-146
15. Lee IM, Manson CH, Hennekens CH, et al. Low-dose aspirin and risk of cancer: the Physician's Health Study [abstract]. Am J Epidemiol 1995; 141:328
16. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995; 24:107-109
17. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320:1642-1646
18. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and lung cancer in women. Br J Cancer 2002; 87:49-53
19. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9:693-695
20. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002; 2:31
21. Friis S, Sørensen HT, McLaughlin JK, et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88:684-688
22. Sørensen HT, Friis S, Nørgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88:1687-1692
23. Holick CN, Michaud DS, Leitzmann MF, et al. Aspirin use and lung cancer in men. Br J Cancer 2003; 89:1705-1708
24. Muscat JE, Chen SQ, Richie JP Jr, et al. Risk of lung carcinoma among users of nonsteroidal anti-inflammatory drugs. Cancer 2003; 97:1732-1736
25. United States Surgeon General. Reducing the health consequences of smoking: 25 years of progress. Washington, DC: US Government Printing Office, 1989
26. Witschi H. Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp Lung Res 2000; 26:743-755
27. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311
28. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998; 90:1609-1620
29. Yao R, Rioux N, Castonguay A, et al. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res 2000; 26:731-742
30. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000; 30:73-81
31. Hida T, Kozald K, Muramatsu H, et al. Cyclooxygenase 2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6:2006-2011
32. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637-2645
33. Xu XC. COX-2 inhibitors in cancer treatment and prevention: a recent development. Anticancer Drugs 2002; 13:127-137
34. Gardiner PS, Gilmer JF. The medicinal chemistry implications of the anticancer effects of aspirin and other NSAIDs. Mini Rev Med Chem 2003; 3:461-470
35. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9:28-35
36. Flanders WD, Lally CA, Zhu BP, et al. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res 2003; 63:6556-6562
37. Khuder SA, Dayal HH, Mutgi AB, et al. Effect of cigarette smoking on major histological types of lung cancer in men. Lung Cancer 1998; 22:15-21
38. Barbone F, Bovenzi M, Cavallieri F, et al. Cigarette smoking and histologic type of lung cancer in men. Chest 1997; 112:1474-1479
39. Hasturk S, Kemp B, Kalapurakal SK, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall lung carcinoma. Cancer 2002; 94:1023-1031
40. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of Cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58:3761-3764
41. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001
42. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5:1001-1005
43. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7:861-867